TSx-Cover

Rosacea

Suggested Reading

Fowler J et al (2012). Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies, BJD, 166:633-641.

Fowler J et al (2013) Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized double-blind, vehicle-controlled pivotal studies, JDD, 12(6): 650-656.

Del Rosso JQ (2012) Advances in understanding and managing rosacea: Part 1 & 2, J Clin Aesth Derm, 5(3):16-25, 26-36.

Webster GF (2009) Rosacea. Med Clin North Am. 2009 93(6):1183-94.

van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S (2007) Systematic review of rosacea treatments. J Am Acad Dermatol. 56(1):107-15.

Chamaillard M, Mortemousque B, Boralevi F, et al (2008) Cutaneous and ocular signs of childhood rosacea, Arch Dermatol, 144:167-171

Powell FC (2005) Clinical practice: Rosacea, NEJM 352: 793-803.

Odom R, Dahl M, Dover J, et al (2009) Standard management options for rosacea, part 2: options according to subtype, Cutis 84: 97-104.

Odom R, Dahl M, Dover J, et al (2009) Standard management options for rosacea, part 1: overwiev and broad spectrum of care, Cutis 84: 43-47.

Del Rosso JQ, Baldwin H, Webster G et al (2008) American Acne & Rosacea Society medical management guidelines, J Drugs Dermatol 7(6): 531-533.